C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer.

Abstract

This study tries to evaluate the associations between circulating C-reactive protein (CRP) and the overall survival of patients with non-small cell lung cancer (NSCLC). One hundred ninety-two patients with advanced NSCLC who treated with chemotherapy were enrolled in this study. The cut-off value of CRP concentration was 5.0 mg/L. The patients were divided into low, intermediate and high 3 groups respectively according to the baseline level of CRP before the treatment. Kaplan–Meier analysis and Cox proportional-hazard models were used to evaluate the relationship between the CRP and overall survival time of patients. After adjusting for age, gender, smoking history, pathologic type, CRP was a significant independent impact which predicts the survival prognosis of patients with NSCLC. For all patients, the hazard ratio with high CRP levels for NSCLC-specific survival was 1.83 [95%confidenceinterval (CI) = 0.96, 3.48] compared with low CRP levels. The level of CRP was significantly correlated with survival time (hazard ratio = 1.77; 95% CI = 0.73, 4.26) for the patient with first-line chemotherapy. Patients with high level of circulating CRP also responded poorly to chemotherapy. A high level of circulating CRP was associated with a poor response and worse survival in patients with NSCLC.

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

“…72 Similarly, serum inflammatory cytokines have been shown to be predictive of both thoracic toxicity and survival after thoracic radiotherapy. [73][74][75][76][77] Although these data raise concerns, we are not entirely sure how they can manifest in patients with COVID-19 as data on this pandemic are still emerging, and the degree of morbidity seen has been variable. For some patients, the effects of the virus and lung cancer therapies may simultaneously damage pulmonary tissue and increase the chance of pneumonitis.…”

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer

“…C-reactive protein (CRP): An acute-phase plasma protein that is elevated in systemic inflammation and is commonly used as an inflammatory marker. CRP has been associated to primary risk of lung cancer and survival in patients with lung cancer [ 8 , 32 ]. Neutrophil-to-lymphocyte ratio (NLR): One of the cell-count based markers representing systemic inflammation.…”

“…Especially in lung cancer, inflammatory mechanisms play an important role in carcinogenesis and cancer progression [ 5 , 6 , 7 ]. Biomarkers of systemic inflammation including c-reactive protein (CRP), lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR) and lymphocyte-platelet ratio (PLR) as indicators of the cellular-mediated inflammatory response, have been reported to be associated with survival in different subgroups of patients with lung cancer [ 8 , 9 , 10 , 11 , 12 ].…”

Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic

“…59 Similarly, serum inflammatory cytokines have been shown to be predictive of both thoracic toxicity and survival following thoracic radiotherapy. [60][61][62][63][64] While these data raise concerns, we are not entirely sure how they can manifest in patients with COVID-19 as the data on this pandemic are still emerging and the degree of morbidity seen has been variable. The effects of the virus and lung cancer therapies may simultaneously damage pulmonary tissue and increase the chance of pneumonitis.…”